Med Ad News, PharmaLive.com sold

Share this article:

Med Ad News and PharmaLive.com publisher, Engel Publishing Partners, has been acquired by Los Angeles-based Canon Communications, Canon announced today. Financial terms of the deal were not disclosed.

Canon, a division of Apprise Media, produces magazine titles and trade shows focused on the medical device, specialty packaging, materials processing, and plastics processing industries.

Canon currently maintains several medical titles including MD&DI (Medical Device & Diagnostic Industry), Medical Product Manufacturing News, Medical Electronics Manufacturing, European Medical Device Manufacturer and others. Canon's digital media holdings include the medical device design and engineering portal, Medical Device Link; online magazine, Advanced Design & Manufacturing (AD&M) and various e-newsletters and e-publications.

Next month, Canon will launch its BIOMEDevice trade show, to provide “a forum for areas where the pharmaceutical and medical device manufacturing markets are converging,” said Charles McCurdy, Canon CEO.

Engel Publishing, based in Newtown, PA, was established in 1982. Its monthly Med Ad News publication covers business and marketing activities in the pharmaceutical industry.

Engel's R&D Directions title was established in 1995 and is published 10 times a year. R&D Directions' target audience is comprised of research and development professionals at pharmaceutical companies.

PharmaLive.com reports 150,000 unique visitors each month with 65,000 professionals registered to receive its e-newsletters.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...